GlassScriptPhysician profile
Evan Gleaves
NPI 1477181246
$4,146.65
in general payments reported to CMS, 2019-2025
29 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.63 · 2023: $212 · 2024: $1,528 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330 · Travel and Lodging: $558 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.68 |
| Travel and Lodging | $558.01 |
| Education | $246.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,199.53 | 2024-2025 | Impella |
| Medtronic, INC. | $616.59 | 2025 | |
| Pfizer INC. | $271.39 | 2023-2025 | |
| Abbott Laboratories | $263.99 | 2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $205.19 | 2025 | |
| Merck Sharp & Dohme LLC | $159.73 | 2025 | Winrevair, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.65 | 2023 | |
| Janssen Pharmaceuticals, INC | $131.17 | 2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $123.48 | 2023-2025 | Onpattro, Amvuttra |
| Chiesi USA, INC. | $121.90 | 2024-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $103.81 | 2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $100.73 | 2024-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $86.51 | 2021-2025 | Brilinta, Wainua, Farxiga |
| Verona Pharma, INC. | $85.70 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $75.14 | 2024-2025 | Giapreza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $64.47 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $59.96 | 2025 | Eliquis |
| Stryker Corporation | $48.88 | 2025 | Flowtriever |
| Bayer Healthcare Pharmaceuticals INC. | $46.79 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.81 | 2025 | Lifevest |
| Philips North America LLC | $31.00 | 2024 | (Ck4) Mcot |
| Edwards Lifesciences Corporation | $25.49 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shockwave Medical, INC | $25.29 | 2025 | |
| Vifor Pharma, INC. | $25.10 | 2024 | Zemaira |
| United Therapeutics Corporation | $18.50 | 2025 | Tyvaso |
| Novo Nordisk INC | $17.94 | 2024 | Rybelsus, Ozempic |
| Csl Behring | $16.52 | 2025 | Kcentra |
| Sanofi-Aventis U.S. LLC | $16.44 | 2023 | |
| Amgen INC. | $14.95 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Gleaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.